The global bifurcation lesions market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 2.5 Billion |
Market Forecast in 2033
|
USD 3.8 Billion |
Market Growth Rate (2025-2033) | 4.4% |
A bifurcation lesion refers to the narrowing of the coronary artery adjacent to the origin of a significant side branch (SB). It is prone to develop atherosclerotic plaque due to turbulent blood flow and high shear stress. It is treated using techniques like analysis, procedure duration, X-ray exposure, and long-term follow-up. Moreover, three-dimensional (3D) angiography and multi-slice computed tomography are utilized for measuring the bifurcation angles. With the advances in devices, imaging, adjunctive pharmacotherapy, and vascular access, the management of complex cases of bifurcation lesions is becoming possible worldwide.
A significant rise in the occurrence of coronary artery disease (CAD) is increasing the risk of developing bifurcation lesions. This represents one of the key factors bolstering the market growth. Besides this, the approval of innovative devices, increasing insurance coverage, and improving imaging modalities are also strengthening the market growth. Moreover, the rising geriatric population, which is more likely to develop medical ailments, along with supportive initiatives undertaken by governments of various countries for reimbursement, is supporting the market growth. The increasing medical tourism, the escalating demand for minimally invasive (MI) procedures and the improving healthcare infrastructure are some of the other factors contributing to the growth of the market. Apart from this, the ongoing research on novel treatment techniques is driving the market. For instance, researchers are studying the effectiveness of the Szabo 2-stent technique for complex bifurcations lesions with high compromise risk or fatal consequences of SB occlusion. Furthermore, a wide range of clinical trials on stents and balloons, in confluence with the increasing number of skilled healthcare professionals, is anticipated to decrease risks associated with bifurcation lesions treatment and influence the market positively.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bifurcation lesions market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on types and application.
Breakup by Types:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.) and Terumo Corporation.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Types, Application, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.) and Terumo Corporation |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global bifurcation lesions market was valued at USD 2.5 Billion in 2024.
We expect the global bifurcation lesions market to exhibit a CAGR of 4.4% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective bifurcation lesions treatments to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment or healthcare professionals.
The growing prevalence of Coronary Artery Disease (CAD), along with the increasing focus on clinical trials on stents and balloons to decrease risks associated with bifurcation lesions treatment, is primarily driving the global bifurcation lesions market.
Based on the application, the global bifurcation lesions market can be bifurcated into coronary vascular and peripheral vascular. Currently, coronary vascular exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global bifurcation lesions market include Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.), and Terumo Corporation.